In vivo CAR-T drug targeting CD20 based on mRNA-LNP therapy (The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army)

N/A

Report date: 2026/04/23 20:00:25

Base Information

Drug NameIn vivo CAR-T drug targeting CD20 based on mRNA-LNP therapy (The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army)

Drug Alias NameN/A

ClassificationCell and gene therapy > Gene therapy > LNPCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy > In vivo CAR-T therapyCell and gene therapy > Cell therapy > In vivo cell therapy > In vivo CAR-T therapy

Mechanisms of ActionB-lymphocyte antigen CD20 modulatorsT lymphocyte replacements

TargetsB-lymphocyte antigen CD20

Therapy Area/IndicationsHematologic Neoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

China Registration ClassN/A

Develop Information

Active CompaniesThe 923rd Hospital of Joint Logistics Support Force of People's Liberation Army

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsN/A

Other Information

ATC CodeN/A